Clinical Trial Update: A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial (PIPER) evaluating pembrolizumab plus platinum and gemcitabine as first-line therapy for recurrent/metastatic head and neck squamous cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Pembrolizumab (Keytruda) (pembrolizumab)
• Platinum-based chemotherapy (platinum-based chemotherapy)

Snippet

Sponsor: University of Malaya | Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING